In view of the high attrition rate of Aβ‐based anti‐AD drugs and the poor compliance of DME patients for anti‐VEGF biologics, Lp‐PLA2 inhibitors can yet be regarded as a potential good choice. Here, PLA2G7 is linked to Alzheimer disease.